The results support further investigation of the Tmod approach to improve the therapeutic window of future blood cancer medicines and provide further proofs of concept for the use of non-HLA-I proteins as blocker antigens for Tmod constructs. This evidence concerns the gene TMOD1 and hematopoietic and lymphoid system neoplasm.